On Wednesday, the European Medicines Agency in London announced it would review all drugs of this type.
As they sat at the former lab director's dining table that night, they watched Edward Scolnick, who had been a champion of the drug before he retired, take in the implications of the data and become ``despondent,'' they said.
Meanwhile, the European Medicines Agency in London announced it would review drugs similar to Vioxx.
That is one reason doctors and patients welcomed the new NSAIDs known as Cox-2 inhibitors -- Vioxx, Celebrex and Bextra -- as they started entering the market in the
